Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01658007 · ClinicalTrials.gov registry record · Early Phase 1

Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma

A Early Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.

Terminated
Registry status
Early Phase 1
Development phase
3
Enrollment target

NCT01658007: Clinical Trial Early Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.

NCT01658007 is a Early Phase 1 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01658007, a Early Phase 1 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.

TERMINATED
Registry status
Early Phase 1
Development phase
3 participants
Enrollment target

Study Summary

The investigators want to learn about treating relapsed/refractory lymphoblastic leukemia and lymphoma with a drug called sirolimus. The investigators are using sirolimus along with other cancer drugs that are often given to patients with relapsed leukemia and lymphoma. The main purpose of this study is to determine if sirolimus can be given safely in combination with standard drugs used to treat relapsed lymphoblastic leukemia/lymphoma.

Primary Outcome

The safety of the regimen will be assessed by the occurrence of unexpected or severe adverse events attributable to sirolimus

Interventions

  • DRUG Sirolimus

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2012-08
Est. Completion 2017-01
Phase Early Phase 1

Why NCT01658007 stopped before completion

NCT01658007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 1 intervention - of which Sirolimus is the first listed.

NCT01658007 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01658007 about?

NCT01658007 is a clinical study titled "Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma". The investigators want to learn about treating relapsed/refractory lymphoblastic leukemia and lymphoma with a drug called sirolimus. The investigators are using sirolimus along with other cancer drugs that are often given to patients with relapsed leukemia and lymphoma. The main purpose of this stu...

What is the current status of trial NCT01658007?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2012-08. Estimated completion is 2017-01.

What interventions are being tested in trial NCT01658007?

The interventions under investigation include: Sirolimus (DRUG).

Who is sponsoring clinical trial NCT01658007?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01658007's enrollment target sits among peer trials

3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01658007, the US trial registry maintained by the National Library of Medicine. NCT01658007 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.